164 related articles for article (PubMed ID: 8911695)
1. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils.
Jutel M; Müller UR; Fricker M; Rihs S; Pichler WJ; Dahinden C
Clin Exp Allergy; 1996 Oct; 26(10):1112-8. PubMed ID: 8911695
[TBL] [Abstract][Full Text] [Related]
2. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures.
Jutel M; Pichler WJ; Skrbic D; Urwyler A; Dahinden C; Müller UR
J Immunol; 1995 Apr; 154(8):4187-94. PubMed ID: 7706753
[TBL] [Abstract][Full Text] [Related]
3. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2.
Novak N; Mete N; Bussmann C; Maintz L; Bieber T; Akdis M; Zumkehr J; Jutel M; Akdis C
J Allergy Clin Immunol; 2012 Nov; 130(5):1153-1158.e2. PubMed ID: 22698521
[TBL] [Abstract][Full Text] [Related]
4. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.
Pierkes M; Bellinghausen I; Hultsch T; Metz G; Knop J; Saloga J
J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):326-32. PubMed ID: 9949326
[TBL] [Abstract][Full Text] [Related]
5. Ultra rush bee venom immunotherapy does not reduce cutaneous weal responses to bee venom and codeine phosphate.
Jutel M; Skrbic D; Pichler WJ; Müller UR
Clin Exp Allergy; 1995 Dec; 25(12):1205-10. PubMed ID: 8821301
[TBL] [Abstract][Full Text] [Related]
6. Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children.
Cichocka-Jarosz E; Dorynska A; Pietrzyk JJ; Spiewak R
Immunotherapy; 2011 Aug; 3(8):1013-7. PubMed ID: 21843104
[TBL] [Abstract][Full Text] [Related]
7. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.
Müller U; Akdis CA; Fricker M; Akdis M; Blesken T; Bettens F; Blaser K
J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):747-54. PubMed ID: 9648701
[TBL] [Abstract][Full Text] [Related]
8. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy.
McHugh SM; Deighton J; Stewart AG; Lachmann PJ; Ewan PW
Clin Exp Allergy; 1995 Sep; 25(9):828-38. PubMed ID: 8564721
[TBL] [Abstract][Full Text] [Related]
9. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.
Korošec P; Žiberna K; Šilar M; Dežman M; Čelesnik Smodiš N; Rijavec M; Kopač P; Eržen R; Lalek N; Bajrović N; Košnik M; Zidarn M
Clin Exp Allergy; 2015 Oct; 45(10):1579-89. PubMed ID: 26046807
[TBL] [Abstract][Full Text] [Related]
10. Honeybee venom secretory phospholipase A2 induces leukotriene production but not histamine release from human basophils.
Mustafa FB; Ng FS; Nguyen TH; Lim LH
Clin Exp Immunol; 2008 Jan; 151(1):94-100. PubMed ID: 18005261
[TBL] [Abstract][Full Text] [Related]
11. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.
Akdis CA; Akdis M; Blesken T; Wymann D; Alkan SS; Müller U; Blaser K
J Clin Invest; 1996 Oct; 98(7):1676-83. PubMed ID: 8833918
[TBL] [Abstract][Full Text] [Related]
12. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.
Siegmund R; Vogelsang H; Machnik A; Herrmann D
J Allergy Clin Immunol; 2000 Dec; 106(6):1190-5. PubMed ID: 11112905
[TBL] [Abstract][Full Text] [Related]
13. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
14. Mononuclear blood cell sulfidoleukotriene generation in the presence of interleukin-3 and whole blood histamine release in honey bee and yellow jacket venom allergy.
Maly FE; Marti-Wyss S; Blumer S; Cuhat-Stark I; Wüthrich B
J Investig Allergol Clin Immunol; 1997; 7(4):217-24. PubMed ID: 9330184
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of FcεRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization.
Čelesnik Smodiš N; Šilar M; Eržen R; Rijavec M; Košnik M; Korošec P
PLoS One; 2014; 9(4):e94762. PubMed ID: 24733549
[TBL] [Abstract][Full Text] [Related]
16. Relevance of basophil histamine release changes during venom immunotherapy.
Stephan V; Kühr J; Urbanek R
Allergy; 1989 Sep; 44(7):453-9. PubMed ID: 2479278
[TBL] [Abstract][Full Text] [Related]
17. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
Bellinghausen I; Metz G; Enk AH; Christmann S; Knop J; Saloga J
Eur J Immunol; 1997 May; 27(5):1131-9. PubMed ID: 9174602
[TBL] [Abstract][Full Text] [Related]
18. Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response.
Čelesnik N; Vesel T; Rijavec M; Šilar M; Eržen R; Košnik M; Kloft Žitnik SE; Avčin T; Korošec P
Allergy; 2012 Dec; 67(12):1594-600. PubMed ID: 23066930
[TBL] [Abstract][Full Text] [Related]
19. The effect of interleukin 3 upon IgE-dependent and IgE-independent basophil degranulation and leukotriene generation.
Kurimoto Y; De Weck AL; Dahinden CA
Eur J Immunol; 1991 Feb; 21(2):361-8. PubMed ID: 1705512
[TBL] [Abstract][Full Text] [Related]
20. High sensitivity of basophils predicts side-effects in venom immunotherapy.
Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
